Thursday, February 02, 2017 8:26:10 PM
1.Clinical proof of concept for platform mechanism.
2.Favorable safety profile and low toxicities to-date.
3.Pan-antigen `killer`T cell activation and expansion.
4.Applicable to multiple cancers and infectious diseases.
5.Ready-to-use;scalable, low cost manufacturing.
6.Unencumbered commercialization rights.
The gp96 platform has proven to be both safe and effective in many cancer and viral applications. It provides an off-the-shelf rapid treatment at about 5% of the COGS of competitors. And the company holds 100% of the commercialization rights.
The six 2017 Targeted Goals are as follows.
1.Complete enrollment for HS-110 + nivolumab combo Ph 1b trial.
2.Report additional topline data for HS-110 + nivolumab trial.
3.Open additional trial arms to evaluate HS-110 with new I-O combinations.
4.Report topline 2-year data for HS-410 Ph 2 trial.
5.In-licence new programs to complement existing T cell-activating technologies.
6.Pursue non-dilutive grant funding to advance existing programs.
The first 3 goals indicate to me that the HS-110 + nivolumab trial is going well. In December they reported on the first 8 patients and the results were encouraging. They only needed 10 more patients to complete the 1b portion of the trial. They must be close to recruiting this number and as it is an open label trial they know how things are going. They could have the topline data any time now. This is important because Wolf said in his presentation that BMS, Merck and AZN know about this trial and `...they are waiting for the results of this trial.` IMO the company could be in a position to partner with good 1b results. And although they did not target it, they have made it clear that they will soon announce a ComPACT trial.
They should certainly have the bladder cancer HS-410 Ph2 topline 2-year data by September and be ready to make it public in October. The current BCG treatment commonly has a good 1 year response rate but by year 2 recurrence can be as high as 40%. HS-410 produced an immune response not seen with BCG. The 2 year results will be of interest.
They intend to in-licence new programs to complement their existing T cell activating technologies. This is very interesting. they must have something in mind. Did Dr. Hutchins bring along some new ideas.
And what is meant by non-dilutive grant funding to advance existing programs`...the University of Miami has had government grant funding for the Gp96 viral programs in the past...I expect this to continue for the Zika trial. But `grants`to further the other existing programs...what could they be....part of a collaboration or partnership... There is a lot of news to come.
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent NHWK News
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/03/2024 08:00:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/03/2024 11:18:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/02/2024 12:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2024 12:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2024 12:10:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2024 09:00:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:52:07 PM
- Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 03/13/2024 10:17:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2024 10:01:13 AM
- Scorpius Holdings, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 03/12/2024 09:00:59 PM
- Scorpius Holdings, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 03/08/2024 05:20:00 AM
- Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/07/2024 09:18:08 PM
- Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:34:04 PM
- NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:00:09 PM
- NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:30:14 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:30:09 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client • GlobeNewswire Inc. • 01/16/2024 01:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM